CD38 and neoplasm: Using a second-generation CD19 CAR paired with a CD38 CCR with dual-co-stimulatory domains, Katsarou demonstrated the improved targeting of ultra-low-density CD19 tumor cells (∼20 molecules/cell) that were resistant to second-generation CD19-CAR T cells.232